Senile cardiac amyloidosis

FDA Places Clinical Hold on Two Intellia CRISPR Trials After Life-Threatening Liver Toxicity Case

3 months ago talkbio0Tagged ATTR-CM, ATTR-PN, Clustered Regularly Interspaced Short Palindromic Repeats, gene therapy, Intellia, Liver, MAGNITUDE trial, Nexiguran, Senile cardiac amyloidosis, Study on Hold, Toxicity aspects, United States Food and Drug Administration, ziclumeran

FDA; Intellia; CRISPR; clinical hold; liver toxicity; nexiguran ziclumeran; MAGNITUDE trial; transthyretin amyloidosis; ATTR-CM; ATTR-PN; gene therapy

Intellia Pauses Two CRISPR Trials After Severe Liver Toxicity Hospitalizes Patient

3 months ago talkbio0Tagged Clustered Regularly Interspaced Short Palindromic Repeats, Gene Modification, Hospitalization, Intellia, Liver, Pauses, Phase 3 Clinical Trials, Safety, Senile cardiac amyloidosis, Toxicity aspects

Intellia Therapeutics; CRISPR; transthyretin amyloidosis; Phase III trials; gene editing; liver toxicity; patient hospitalization; safety pause

FDA Approves Attruby (Acoramidis) for ATTR-CM, Offering New Hope for Patients with Transthyretin Cardiac Amyloidosis

1 year ago talkbio0Tagged Acoramidis, Approved, ATTR-CM, Attruby, BridgeBio Pharma, Heart Diseases, Prealbumin, Senile cardiac amyloidosis, United States Food and Drug Administration

Attruby, Acoramidis, FDA Approval, ATTR-CM, Transthyretin Cardiac Amyloidosis, BridgeBio Pharma, Heart Disease Treatment